Dexketoprofen
Dexketoprofen is a nonsteroidal anti-inflammatory drug (NSAID). It is manufactured by Menarini, under the tradename Keral. It is available in the UK, as dexketoprofen trometamol, as a prescription-only drug and in Latin America as Enantyum, produced by Menarini. Also, in Italy and Spain it is available as an over-the-counter drug (OTC) under the trade name Enandol or Enantyum. In Hungary it is available from a pharmacy as Ketodex. In Turkey, it is an over the counter medicine under the name Arveles. In Latvia, Lithuania and Estonia it is available as an OTC under the tradename Dolmen. In Mexico it is available in tablet form as Stadium made by Menarini. It is the dextrorotatory stereoisomer of ketoprofen. — Wikipedia
Clinical trial activity
57 trials · 49 clinical orgs · 0 marketing orgs
Earliest trial started Feb 1, 2011 (NCT01307020)
Timeline
Indications
Approved for
Studied for
- Acute Pain · Phase 4
- Analgesia · Phase 4
- Analgesics, Opioid · Phase 4
- Anesthesia · Phase 4
- Anesthesia, Spinal · Phase 4
- Ankle Injuries · Phase 4
- Arthroplasty, Replacement, Hip · Phase 4
- Fractures, Bone · Phase 4
- General Surgery · Phase 4
- Healthy Volunteers · Phase 1
- Hysteroscopy · Phase 3
- Laparoscopy · Phase 4
- Low Back Pain · Phase 4
- Mental Disorders · Phase 4
- Migraine Disorders · Phase 4
- Migraine without Aura · Phase 4
- Musculoskeletal Pain · Phase 4
- Pain · Phase 4
- Pain Management · Phase 2/Phase 3
- Pharyngitis · Phase 4
- Postoperative Pain · Phase 4
- Psychological Distress · Phase 4
- Pulpitis · Phase 4
- Renal Colic · Phase 4
- Temporomandibular Joint Disorders · Phase 4
- Traumatology · Phase 3
- Virtual Reality · Phase 2/Phase 3
Mechanism of action
- CyclooxygenaseINHIBITOR
Cyclooxygenase inhibitor
Ketoprofen is a non-steroidal anti-in¿ammatory drug. It is a racemic mixture and its analgesic ef¿cacy is due to the (S)-enantiomer, dexketoprofen. The analgesic action of the (R)-enantiomer is considered to be less signi¿cant, but causes the majority of adverse effects, that is gastric mucosa irritation. Its mechanism of action is the non-selective inhibition of cyclooxygenase-1 and cyclooxygenase-2.
Dexketoprofen was found to be a potent inhibitor of the prostaglandin F2 alpha (PGF2 alpha) production in rat brain (IC50 = 6.2 nM)
Chemistry & pharmacology
SMILES
C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1- Mol. weight
- 254.29 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaDexketoprofen ↗
- ChEMBLCHEMBL75435 ↗
Also known as
- adolquir
- badyket
- brilma
- dexketoprofen
- dexketoprofen
- dexketoprofen
- dexketoprofen
- dexketoprofen
- dexketoprofen
- dexketoprofen trometamol
- dexketoprofen trometamol
- dexketoprofen trometamol
- dexketoprofen trometamol
- dexketoprofen trometamol
- dexketoprofen trometamol
- dexketoprofen trometamol
- enangel
- enantyum
- enantyum
- enantyum
- keral
- keral
- keral
- ketesse
- (+)-ketoprofen
- quiralam
- quirgel
- (s)-ketoprofen
- sympal
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07176572 | Phase 4 | Mar 1, 2026 | Adiyaman University |
| NCT07098962 | Phase 2/Phase 3 (Phase 3) | Aug 15, 2025 | Kastamonu University |
| NCT07057752 | Phase 2/Phase 3 (Phase 3) | Aug 1, 2025 | Kastamonu University |
| NCT07248540 | N/A | Jul 1, 2025 | Gaziosmanpasa University |
| NCT06878014 | Phase 4 | Mar 4, 2025 | Silesian University of Medicine |
| NCT06563271 | Phase 4 | Dec 1, 2023 | Ankara Etlik City Hospital |
| NCT06060236 | Phase 4 | Sep 1, 2023 | Ankara Yildirim Beyazıt University |
| NCT06404177 | Phase 3 | Jul 15, 2023 | Hôpital Universitaire Sahloul |
| NCT05176158 | N/A | Jul 1, 2023 | McGill University, Universidad Complutense de Madrid |
| NCT06916234 | Phase 4 | Jan 10, 2023 | Van Yuzuncu Yil University |
| NCT05001555 | Phase 3 | Nov 29, 2021 | CICMEX Centro de Investigación Clínica de México, Icaro Investigación en Medicina S.A. de C.V., INBIOMEDyC, Laboratorios Silanes S.A. de C.V., Mediadvance Clinical S.A.P.I. de C.V. |
| NCT06932367 | Phase 4 | Aug 1, 2021 | Ataturk University |
| NCT04582032 | N/A | Nov 1, 2020 | Ankara Yildirim Beyazıt University |
| NCT04533568 | Phase 4 | Oct 31, 2020 | Kecioren Education and Training Hospital |
| NCT05170841 | Phase 4 | Sep 17, 2020 | Menarini Group, University of L'Aquila |
| NCT04526132 | Phase 3 | Sep 14, 2020 | Central South University, Yiling Pharmaceutical Inc. |
| NCT05125796 | N/A | Sep 1, 2020 | Adiyaman University |
| NCT04442009 | N/A | Jun 22, 2020 | Istanbul Medipol University |
| NCT04161690 | Phase 2 | Nov 6, 2019 | KAT General Hospital |
| NCT05529290 | Phase 4 | Jul 16, 2019 | Van Yuzuncu Yil University, Yuzuncu Yıl University |
Organizations
Research & Development (49)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Menarini Group | For profit | 6 | 6 | 4 | 2011 |
| Pamukkale University | Academic/Hospital | 6 | 6 | 2 | 2015 |
| Erciyes University | Academic/Hospital | 5 | 3 | 2 | 2012 |
| Yiling Pharmaceutical Inc. | For profit | 4 | 4 | 3 | 2017 |
| University of Oxford | Academic/Hospital | 3 | 0 | 2 | 2011 |
| Adiyaman University | Academic/Hospital | 2 | 2 | 2 | 2020 |
| Ankara Yildirim Beyazıt University | Academic/Hospital | 2 | 2 | 2 | 2020 |
| Ataturk University | Academic/Hospital | 2 | 2 | 1 | 2019 |
| Central South University | Academic/Hospital | 2 | 0 | 2 | 2019 |
| Erzincan University | Academic/Hospital | 2 | 2 | 1 | 2017 |
| Gaziosmanpasa University | Academic/Hospital | 2 | 2 | 2 | 2019 |
| Jilin University | Academic/Hospital | 2 | 0 | 1 | 2017 |
| Kastamonu University | Academic/Hospital | 2 | 2 | 1 | 2025 |
| KAT General Hospital | Academic/Hospital | 2 | 2 | 1 | 2019 |
| Laboratorios Silanes S.A. de C.V. | For profit | 2 | 2 | 2 | 2019 |
| Van Yuzuncu Yil University | Academic/Hospital | 2 | 1 | 1 | 2019 |
| Akdeniz University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Ankara Etlik City Hospital | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Cairo University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| CICMEX Centro de Investigación Clínica de México | Academic/Hospital | 1 | 0 | 1 | 2021 |